Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion. This growth was fueled by a 54% surge in sales of its proprietary medicines, most notably Abkinley, which generated $468 million, which was a 67% year-over-year increase. The company also benefited from the continued success of its royalty portfolio, particularly Darzalex, which is projected to reach net sales of up to $16.4 billion in 2026.
The company strategically expanded throughout the year, highlighted by the acquisition of ProfoundBio and its promising late-stage asset, Rina-S. Genmab particularly expanded its clinical pipeline with three new Phase 3 trials and secured FDA approval for Abkinley in second-line follicular lymphoma.
However, the company faced a hurdle with the Phase 3 EPCOR DLBCL-1 trial: while Genmab met its progression-free survival goals, it missed statistical significance for overall survival, leading to ongoing discussions with regulatory authorities to address trial biases like COVID-19 and the impact of subsequent therapies.
Genmab is a biotechnology company that develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
